Provigil (Modafinil) and Metformin Interaction: Safety, Risks, and Clinical Guidance

Modafinil (brand name Provigil) is a schedule IV wakefulness-promoting agent approved for narcolepsy, obstructive sleep apnea-related excessive sleepiness, and shift work disorder. Metformin (brand names include Glucophage and Glucophage XR) is a biguanide antihyperglycemic used first-line for type 2 diabetes. They are unrelated drug classes and this page addresses only the interaction between them, not modafinil's other drug interactions or metformin's use in other conditions.

Direct answer: Modafinil and metformin do not share a metabolic pathway, so there is no established pharmacokinetic interaction between them. Metformin is eliminated unchanged by the kidneys and is not a substrate of the CYP enzymes that modafinil affects, which is documented in both drugs' FDA-approved prescribing information. The open question is pharmacodynamic, not pharmacokinetic: whether modafinil's stimulant effects can raise blood glucose enough to matter for glycemic control in some patients. That question has not been answered by a dedicated clinical trial in people taking both drugs, so the sensible approach is monitoring rather than either avoidance or reassurance without follow-up.

Why the useful question isn't "do they interact" but "what kind of effect could occur"

Most interaction checkers return a "minor" or "no known interaction" flag for this pair, and that flag is correct as far as it goes. But a flat "no interaction" answer can mislead a patient with diabetes who is close to their HbA1c target, because it implies nothing needs watching. The more accurate framing is that there are two separate questions with two separate answers: a pharmacokinetic question (does modafinil change metformin blood levels, or vice versa) which is answered no, and a pharmacodynamic question (could modafinil's stimulant activity push glucose upward in a way that offsets some of metformin's benefit) which is plausible but not quantified in the available literature.

How the two drugs are cleared from the body

Modafinil undergoes substantial hepatic metabolism, primarily amide hydrolysis, and at therapeutic doses (200 to 400 mg/day) it acts as a moderate inducer of CYP3A4 and an inhibitor of CYP2C19. This is described in the FDA-approved Provigil label (accessdata.fda.gov). These enzyme effects are clinically relevant for drugs that depend on CYP3A4 or CYP2C19 for clearance, such as hormonal contraceptives, certain benzodiazepines, and some proton pump inhibitors. The exact magnitude of exposure change for any specific co-medication should be confirmed against the current label text or a pharmacist reference rather than assumed from older percentages circulating online.

Metformin, in contrast, is not metabolized by the liver to any appreciable degree. It is absorbed from the gut, does not bind plasma proteins, and is eliminated largely unchanged through renal tubular secretion and glomerular filtration, per the FDA-approved Glucophage label. Because metformin bypasses CYP-mediated biotransformation entirely, modafinil's induction of CYP3A4 and inhibition of CYP2C19 have no route by which to change metformin blood levels. This is the basis for the "no known pharmacokinetic interaction" classification used by most interaction databases.

The pharmacodynamic concern: opposing effects on glucose

Metformin lowers blood glucose mainly by suppressing hepatic glucose output and improving peripheral insulin sensitivity. Stimulant medications, including modafinil, are pharmacologically capable of raising catecholamine tone, which in theory could nudge hepatic glucose production upward and work against part of metformin's mechanism.

Whether this happens to a clinically meaningful degree in real patients on modafinil is not established. There is no published randomized trial studying modafinil added to a stable metformin regimen, and the animal and small human pharmacology data on modafinil's glucose effects are not strong enough to support a specific quantified claim (for example, a stated mg/dL rise). Any number describing modafinil's average glucose effect should be treated as unverified until checked against a primary study, and this draft intentionally does not repeat one.

The practical implication is that a small subset of patients, particularly those close to their glycemic target, may be more likely to notice an effect than patients with a wide margin between current HbA1c and goal. This is a reason for monitoring, not a reason for alarm.

CYP3A4 induction and CYP2C19 inhibition: relevant to other drugs, not to metformin

Because modafinil's enzyme effects are broad, some interaction databases flag a "monitor" status for almost any drug modafinil is combined with, including metformin. For metformin specifically, this flag is not pharmacologically grounded, since metformin's renal clearance pathway makes it immune to CYP3A4 or CYP2C19 effects.

Where CYP3A4 induction does matter is for other drugs the patient may be taking alongside this combination, such as hormonal contraceptives, cyclosporine, or CYP3A4-metabolized statins. If a patient is on modafinil, metformin, and a third CYP3A4 substrate, the interaction worth auditing is between modafinil and that third drug, not between modafinil and metformin.

CYP2C19 inhibition is similarly not a metformin issue directly, but it can matter indirectly for patients also taking a CYP2C19-metabolized proton pump inhibitor such as omeprazole. Chronic metformin use is independently associated with reduced vitamin B12 absorption, and PPI use is separately associated with altered B12 status. If a patient with diabetes is on modafinil, metformin, and a PPI together, periodic B12 checking (already recommended for long-term metformin users) is a reasonable extra point of attention, though the combined three-drug effect on B12 has not been studied as such.

Renal function and lactic acidosis risk

Metformin's most serious rare adverse event, lactic acidosis, is driven overwhelmingly by impaired renal clearance and acute illness, not by co-administered medications like wakefulness agents. The FDA revised metformin's labeling in 2016 to permit use down to an eGFR of 30 mL/min/1.73 m², a change reflected in current metformin prescribing guidance.

Modafinil has no documented effect on renal function and does not compete with metformin for the renal transporter pathways involved in its tubular secretion. There is no published case report specifically linking modafinil co-administration to metformin-associated lactic acidosis in the material reviewed for this page. That absence is reassuring but should not be read as proof of zero risk; it reflects the limits of current reporting rather than a completed safety study. Standard renal function monitoring for metformin users (roughly every 6 to 12 months, or more often with declining kidney function) remains the appropriate baseline regardless of modafinil use.

What FAERS and interaction databases do and don't show

The FDA's Adverse Event Reporting System (FAERS) public dashboard can be searched for reports mentioning both drugs (fda.gov). A lack of a strong signal there is consistent with a low-risk pharmacokinetic profile, but FAERS is a passive, voluntary reporting system: it cannot rule out a modest or slow-developing pharmacodynamic effect on glucose, and it is not a substitute for a controlled study. Readers should not treat an absence of FAERS reports as definitive evidence of safety, only as one weak, imperfect data point among several.

A monitoring approach a prescriber might use

There is no dedicated clinical trial establishing an optimal monitoring schedule for this specific combination. The following reflects general diabetes monitoring practice recommended by the American Diabetes Association's Standards of Care (diabetesjournals.org), applied to the situation of starting modafinil in a patient already stabilized on metformin. It is a reasonable clinical framework, not a validated protocol specific to this drug pair.

• Before starting modafinil: check current fasting glucose and HbA1c, confirm renal function (eGFR), and review the full medication list for other CYP3A4 or CYP2C19 substrates.
• Around 4 weeks after starting modafinil: recheck fasting glucose. A meaningful upward drift from baseline is worth discussing with the prescriber, though no validated threshold exists for this specific combination; clinical judgment and the patient's distance from their glycemic target matter more than a fixed number.
• Around 12 weeks: recheck HbA1c. If glycemic control has clearly worsened without another explanation (diet change, new corticosteroid, illness), modafinil's contribution should be considered.
• Ongoing: continue standard ADA-recommended diabetes monitoring (HbA1c roughly every 3 to 6 months, periodic renal panel), with no modafinil-specific labs required beyond the initial transition period.

Dose timing

Modafinil reaches peak plasma concentration a few hours after an oral dose, and its plausible glucose effect, if present, would track that peak. Metformin extended-release products are typically dosed with an evening meal. Taking modafinil in the morning, its usual dosing time for wakefulness indications, and metformin ER in the evening keeps the two peaks apart, though this timing strategy is a matter of pharmacologic reasoning and site judgment, not something tested in a trial. It should not be treated as a validated method for preventing a glucose effect that itself remains unconfirmed.

Evidence-status assessment: modafinil plus metformin

When to seek care sooner than a routine follow-up visit

Sustained or rapidly rising fasting glucose readings, new symptoms of hyperglycemia (excessive thirst, frequent urination, blurred vision), or symptoms consistent with lactic acidosis (unusual muscle pain, difficulty breathing, severe fatigue, abdominal pain, or a fast or irregular heartbeat) warrant prompt medical evaluation rather than waiting for a scheduled monitoring visit, particularly in a patient with reduced kidney function or an acute illness.

What is established, what is plausible, and what remains unknown

Established: modafinil and metformin do not interact pharmacokinetically, because metformin is renally cleared and does not depend on the CYP enzymes modafinil affects. Plausible but unproven: modafinil's stimulant properties could modestly raise glucose in some patients, which would partially oppose metformin's effect. Not established: any quantified glucose or HbA1c change specific to this combination, and any increased lactic acidosis risk attributable to modafinil itself. Readers and prescribers should not treat a "no interaction" database flag as equivalent to "no monitoring needed" for patients near their glycemic target, nor should they treat the theoretical glucose concern as a reason to avoid a clinically indicated wakefulness medication without first checking actual glucose trends.